A cfDNA-based DNA methylation classifier for distinguishing prostate cancer from benign prostatic hyperplasia.
A blood test measuring methylation patterns may help doctors distinguish prostate cancer from benign enlargement more reliably than current PSA testing alone.
BACKGROUND: Differentiating benign prostatic hyperplasia (BPH) from prostate cancer (PCa) remains a diagnostic challenge due to overlapping clinical features and the limited specificity of prostate-specific antigen (PSA) testing. GO analysis revealed promoter-proximal hypermethylation enriched for developmental programs, transcription factor activity, and chromatin remodeling, whereas gene body hypermethylation mapped to RNA metabolic processes and intracellular transport, supporting biological plausibility.
What the study was
- Study design
- Observational, biomarker development and validation
- Population
- Patients with suspected prostate disease (PCa vs BPH)
- Category
- Early Detection
- Maturity
- Exploratory
- Journal
- Prostate international
Why it surfaced
Novel cfDNA methylation classifier for non-invasive prostate cancer detection addresses unmet need from PSA non-specificity; liquid biopsy approach directly in EARLY_CANCER_DETECTION watchlist.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.